Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly withdraws phase 2 obesity trial before starting enrollment
The study was designed to test bimagrumab, an asset Lilly acquired in its $1.9 billion Versanis buyout, and blockbuster GLP-1/GIP drug tirzepatide.
Nick Paul Taylor
Sep 25, 2025 8:07am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
Eli Lilly reconsiders UK biotech incubator
Sep 12, 2025 12:09pm
Lilly invites biotechs to use AI platform to develop their drugs
Sep 9, 2025 7:43am
Lilly ends 2 midstage trials for oral GLP-1 drug naperiglipron
Sep 2, 2025 4:32am
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
